Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
Earnings Data
Report Date
Mar 12, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.23Last Year’s EPS
-0.08Same Quarter Last Year
Moderate Buy
Based on 15 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted strong clinical trial results and expansion plans with multiple Phase III trials, indicating significant progress and potential for ivonescimab in various cancer treatments. However, financial concerns and increased expenses were noted as challenges.Company Guidance
Positive Results from HARMONi-6 Study
The HARMONi-6 trial demonstrated a significant progression-free survival benefit for ivonescimab plus chemotherapy with a hazard ratio of 0.60 and a p-value of less than 0.0001. Median progression-free survival was 11.14 months compared to 6.90 months for the control arm, showing a difference of 4.24 months.
Expansion of Phase III Clinical Development Programs
Summit Therapeutics announced the expansion of their Phase III clinical development programs with the initiation of the global Phase III HARMONi-GI3 trial, evaluating ivonescimab in first-line unresectable colorectal cancer, expanding beyond lung cancer.
Upcoming BLA Submission for Ivonescimab
Summit plans to submit a Biologics License Application (BLA) for ivonescimab in Q4 2025 based on the results of the HARMONi study, aiming for approval in the United States.
SMMT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SMMT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 20, 2025 | $20.99 | $20.04 | -4.53% |
Aug 11, 2025 | $28.25 | $25.68 | -9.10% |
May 01, 2025 | $24.67 | $27.90 | +13.09% |
Feb 24, 2025 | $22.12 | $18.84 | -14.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Summit Therapeutics (SMMT) report earnings?
Summit Therapeutics (SMMT) is schdueled to report earning on Mar 12, 2026, After Close (Confirmed).
What is Summit Therapeutics (SMMT) earnings time?
Summit Therapeutics (SMMT) earnings time is at Mar 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SMMT EPS forecast?
SMMT EPS forecast for the fiscal quarter 2025 (Q4) is -0.23.